Durect Posts Narrower Loss in Fiscal Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: Fool
Financial Performance: Durect reported a second-quarter GAAP EPS of $(0.07) and revenue of $0.45 million, both exceeding analyst expectations but showing a decline from the previous year; the company is heavily reliant on its drug candidate larsucosterol for future success amid ongoing financial risks and operational cuts.
Acquisition Plans: The company is preparing for an acquisition by Bausch Health, which includes a cash offer of $1.75 per share and potential future sales milestones, with the deal expected to close in Q3 2025, while management did not provide forward guidance for upcoming quarters.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
